Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to -$52.9 million.

  • Neurocrine Biosciences' Cash from Investing Activities rose 2254.76% to -$52.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$264.4 million, marking a year-over-year decrease of 10851.74%. This contributed to the annual value of -$264.4 million for FY2025, which is 10851.74% down from last year.
  • Latest data reveals that Neurocrine Biosciences reported Cash from Investing Activities of -$52.9 million as of Q4 2025, which was up 2254.76% from -$196.7 million recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Cash from Investing Activities ranged from a high of $63.1 million in Q1 2021 and a low of -$201.8 million during Q4 2023
  • For the 4-year period, Neurocrine Biosciences' Cash from Investing Activities averaged around -$61.2 million, with its median value being -$52.9 million (2025).
  • Examining YoY changes over the last 5 years, Neurocrine Biosciences' Cash from Investing Activities showed a top increase of 12581.82% in 2025 and a maximum decrease of 89635.63% in 2025.
  • Over the past 4 years, Neurocrine Biosciences' Cash from Investing Activities (Quarter) stood at $63.1 million in 2021, then crashed by 419.81% to -$201.8 million in 2023, then soared by 66.15% to -$68.3 million in 2024, then rose by 22.55% to -$52.9 million in 2025.
  • Its Cash from Investing Activities was -$52.9 million in Q4 2025, compared to -$196.7 million in Q3 2025 and -$29.0 million in Q2 2025.